ChChd3, an Inner Mitochondrial Membrane Protein, Is Essential for Maintaining Crista Integrity and Mitochondrial Function

Received for publication, August 3, 2010, and in revised form, November 12, 2010 Published, JBC Papers in Press, November 16, 2010, DOI 10.1074/jbc.M110.171975

Manjula Darshi‡, Vincent L. Mendiola‡, Mason R. Mackey‡, Anne N. Murphy§, Antonius Koller‡, Guy A. Perkins§, Mark H. Ellisman‡¶ and Susan S. Taylor‡¶¶

From the ‡Howard Hughes Medical Institute, §Department of Neurosciences and National Center for Microscopy and Imaging Research, ¶Department of Pharmacology, and ‡¶Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093-0654

The mitochondrial inner membrane (IM) serves as the site for ATP production by hosting the oxidative phosphorylation complex machinery most notably on the cristae membranes. Disruption of the crista structure has been implicated in a variety of cardiovascular and neurodegenerative diseases. Here, we characterize ChChd3, a previously identified PKA substrate of chchD3 protein 3 (ChChd3/FLJ20420/LOC54927/RIKEN cDNA 0610041L09) was previously identified in our laboratory as a PKA substrate in mitochondria and characterized as the proteins responsible for mitochondrial fission. Recent studies have suggested the involvement of IM proteins mitofusin 1 and 2 (Mfn1 and Mfn2) located on the outer membrane (OM) (3) and optic atrophy 1 (OPA1) located on the inner membrane (IM) and intermembrane space (IMS), have been identified as key modulators for mitochondrial fusion (4). On the other hand, the large GTPase dynamin-related protein 1 (DRP1/DLP1/DNM1) (5) along with fission protein 1 homolog (FIS1) (6) on the OM have been well characterized as the proteins responsible for mitochondrial fission. Mutations in some of these proteins have been associated with debilitating conditions such as neurodegenerative diseases, cancer, and type II diabetes (7, 8).

Although significant advances have been made in identifying the proteins involved in mitochondrial morphology and dynamics, very little is known about the protein complexes that control the biogenesis of cristae and crista junctions (CJs). Recent studies have suggested the involvement of IM proteins F1,F0-ATP synthase (9), OPA1 (10, 11), mitofilin (12), and MICS1 (13) in regulating the crista morphology. Furthermore, OPA1 and mitofilin are suggested to be at the CJs and involved in CJ formation and control the CJ opening (10, 12, 14).

Coiled-coil helix coiled-coil helix domain-containing protein 3 (ChChd3/FLJ20420/LOC54927/RIKEN cDNA 0610041L09) was previously identified in our laboratory as a cAMP-dependent protein kinase A (PKA) substrate in mitochondria (15). Proteomic studies and in situ hybridization experiments identified ChChd3 as a highly abundant protein...
ChChd3 Regulates Crista Architecture

at synaptic membranes and in neurons of rat brain throughout the gray matter, dorsal root ganglion, and spinal cord (16). Furthermore, ChChd3 was found to be significantly down-regulated in mitochondrial proteomic analysis of a cell line model of familial amyotrophic lateral sclerosis expressing SOD1 mutant G93A compared with the control cells expressing WT SOD1 (17), suggesting its possible role in the pathophysiology of human disease.

ChChd3 is highly conserved in mammals with human and mouse protein sharing ~92% sequence similarity. Orthologs of the protein are present throughout the metazoans, whereas no homologs are so far seen in fungi or plants. In humans, the ChChd3 gene maps on chromosome 7 (7q32.3-q33), and the coding sequence of the protein has 8 exons that can potentially generate nine splice variants. Full-length ChChd3 has

EXPERIMENTAL PROCEDURES

Antibodies and Plasmids—Polyclonal antibodies against internal peptide sequence corresponding to ChChd3 mouse (QAKKESEHQRLKQARDLERER) and human (QAKKEDQKRLKQAKELDRER) protein sequence were

Gene expression was quantified by qRT-PCR using primers (GCACTACCAGAGCTAACTCAGATAGTACT-3

Isolation and Fractionation of Mitochondria—Mitochondria from mouse liver were isolated, and Histodenz gradient purification was as described previously (24). Mitochondrial subfractions were obtained by swell-shrink procedure and purified by using sucrose gradient ultracentrifugation method (24). Details can be found in supplemental material.

Trypsin Digestion Assay—For trypsin digestion experiments, mitochondria were isolated without protease inhibitors throughout the preparation. 100 μg of freshly isolated mitochondria, swollen mitochondria, and submitochondrial particles were incubated with 2.5 μg of trypsin in 0.125 μM sucrose and 10 mM Tris-HCl, pH 8, for 5–30 min with or without 1% Triton X-100 at room temperature. 200 μg of soybean trypsin inhibitor was added to quench the reaction, and the samples were immediately boiled in the presence of 2× Laemmli sample buffer. 10 μg of the sample was separated on SDS-PAGE and analyzed by immunoblot.

RNA Interference (RNAi)—A 29-mer short hairpin RNA (shRNA), 5'-TATCGAAGACTGCTGGAGGTT-GAAGC-3' corresponding to the nucleotide sequence 489–516 of human ChChd3 in a pRS vector ( OriGene) with U6 promoter and puromycin-resistant gene, was used to generate stable knockdown of ChChd3 in HeLa cells. Control stable cells were generated by using a scrambled sequence 5'-GCACTTTCCAGCTTAATTCACTGATTACT-3' in pRS vector. HeLa cells maintained in DMEM with 10% FBS and 1% GlutaMAX grown to 40% confluency in 35 mm plates were transfected with ChChd3-shRNA or scrambled-control using Turbofectin ( OriGene) according to the manufacturer’s protocol, and stable cell lines were selected in 0.5 μg/ml puromycin (Sigma).

Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR) Measurements—An XF24 extracellular flux analyzer (Seahorse Biosciences) was used to measure the rates of oxygen consumption and extracellular acidification in 24-well plates (Seahorse Biosciences) as described previously (25) with minor modifications. Briefly, cells were plated in growth medium at 3 × 10^4 cells/well 16 h prior to experimentation. The assay medium was unbuffered DMEM (Sigma) supplemented with 10 mM glucose, 10 mM pyruvate, and 2 mM glutamine, pH 7.4, to which 10 × additions were made from the cartridge injection ports. Assay cycles included 3 min of mixing and a 2 min waiting period, followed by 3 min of measurement. An updated algorithm that more accurately accounts for oxygen diffusion through the plastic plate was used for data analysis (26).
ChChd3 Regulates Crista Architecture

**ATP Measurements**—Cellular ATP levels were measured by using a CellTiter-Glo® luminescent cell viability assay (Promega). Briefly, control and ChChd3 knockdown cells were seeded in a 96-well plate with 35,000 cells per well in a 100 μl volume. After 6 h, 100 μl of CellTiter-Glo® reagent was added to each well and mixed for 2 min. After 10 min of incubation at room temperature, luminescence was measured in a GENios microplate reader (Tecan). ATP levels were normalized to protein levels.

**Transmission Electron Microscopy**—Control and ChChd3 knockdown HeLa cells were grown to 60% confluency on poly-d-lysine-coated glass dishes (MatTek) and fixed with 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4, for 5 min at room temperature, followed by 30 min on ice for optimal cellular ultrastructural preservation. The cells were washed five times, 2 min each in ice-cold 0.1 M sodium cacodylate buffer, pH 7.4, with 3 mM calcium chloride. The cultured cells were post-fixed in ice-cold 1% osmium tetroxide (Electron Microscopy Sciences) with 0.8% potassium ferrocyanide (Sigma) and 3 mM calcium chloride (Sigma). After 30 min, the cells were washed five times in double-distilled water for 2 min each and stained en block in ice-cold 2% uranyl acetate overnight to increase membrane contrast. The cultured cells were dehydrated in an ethanol series for 3 min each with 20, 50, 70, and 90% ethanol on ice followed by four changes of 100% ethanol at room temperature. The dehydrated cells were infiltrated in a 1:1 ratio of absolute ethanol to Durcupan ACM epoxy resin (Electron Microscopy Sciences) for 30 min followed by three changes of Durcupan ACM epoxy resin for 1 h each. The dishes with epoxy resin infiltrated culture cells were then placed in a vacuum oven at 60 °C for 48–72 h for the resin polymerization. After polymerization, the coverslips were removed from the dishes, and plastic blocks were sawed out and glued on to dummy blocks. 80 nm ultrathin serial sections were prepared using a Reichert-Jung Ultra-cut E ultramicrotome and Diatome diamond knife. The sections were supported on copper grids/75 mesh (Ted Pella). The 80-nm sections were poststained in Sato lead for 1 min, and the stained sections were imaged onto negatives using a JEM-1200EX I electron microscope operated at 80 kV. The negatives were digitized at 1800 dpi using a Nikon CoolScan system, giving an image size of 4033 × 6010 pixel array and a pixel resolution of 1.77 nm.

**Electron Tomography**—For electron tomography, sections were cut from the same blocks used for conventional transmission electron microscopy at a nominal thickness of 0.5 μm and collected on 100:100 clamshell grids. These sections were poststained for 15 min in a 2% uranyl acetate solution followed by 15 min in Sato lead solution. Two sizes of colloidal gold particles, 15 and 20 nm in diameter, were deposited on opposite sides of the section to serve as fiducial cues. For stability in the beam, the section was coated with carbon. For each reconstruction, a single series of images was collected with a JEOl 4000EX intermediate high voltage electron microscope operated at 400 kV. The specimens were irradiated for about 30 min before initiating a tilt series to limit anisotropic specimen thinning during image collection. During data collection, the illumination was held to near parallel beam conditions. Single-tilt series were recorded using a 4 × 4k slow scan CCD camera controlled by serial EM at 12,000 magnification. Angular increments of 2° usually from −60 to +60° about an axis perpendicular to the optical axis of the microscope were achieved using a computer-controlled goniometer to increment accurately the angular steps. The pixel resolution was 1.2 nm. To improve the signal-to-noise ratio, each image was binned down two times by averaging adjacent pixels so that the final pixel resolution was 2.4 nm. The IMOD software package (27) was used for the complete image processing unless there were problems, and then TxBR software was used to refine the alignment and reconstruction (28). Six reconstructed volumes were analyzed (three control and three ChChd3 knockdown). Volume segmentation was performed by manual tracing in the planes of highest resolution (X-Y) with the program Xvoxtrace (29). The reconstructions were visualized using Analyze (Mayo Foundation) and the surface-rendering graphics of Synu (National Center for Microscopy and Imaging Research) as described by Perkins et al. (29). These programs allow one to step through slices of the reconstruction in any orientation and to model and display features of interest in three dimensions. Measurements of mitochondrial outer and inner boundary and crista membrane surface areas and volumes were made within segmented volumes by the programs Synuarea and Synuvolume, respectively (National Center for Microscopy and Imaging Research, University of California San Diego). Crista junction opening sizes and crista junction densities were measured with ImageJ (National Institutes of Health) using the tomographic volumes.

**Immunoprecipitation**—For immunoprecipitation of transiently expressed FLAG-tagged proteins, HEK293 cells were transfected with Lipofectamine 2000 (Invitrogen) by following the manufacturer’s protocols. Approximately 20 h post-transfection, cells were harvested in buffer A (50 mM Tris-HCl, 150 mM NaCl, 1 mM DTT, 2 mM EDTA, and 1% Triton X-100, pH 7.4) with a protease inhibitor mixture set (Calbiochem), and the cell lysates were incubated with anti-FLAG M2 affinity gel (Sigma) for 2 h at 4 °C. The resin was washed with buffer A (four times) and eluted with Laemmli sample buffer, and samples were analyzed on SDS-PAGE followed by immunoblot.

For immunoprecipitating ChChd3 from mouse liver mitochondria, gradient-purified mitochondria was lysed in buffer A with protease inhibitor mixture set and pre-cleared on protein A-agarose beads (Pierce) for 1 h at 4 °C to prevent any nonspecific binding. Pre-cleared samples were incubated with ChChd3 antibody or the corresponding preimmune serum at 4 °C for 5 h and immunocaptured with protein A-agarose beads. After overnight incubation, the beads were washed five times with 50 mM Tris-HCl, 150 mM NaCl, pH 7.4, with a protease inhibitor mixture, eluted with Laemmli sample buffer, and analyzed on the SDS-PAGE followed by immunoblot.

**Separation of Soluble and Insoluble Fractions**—Soluble/cytoplasmic and insoluble/mitochondrial fractions were isolated from the control and ChChd3 knockdown HeLa cells as described earlier (30). In brief, cells were lysed with the lysis buffer (80 mM KCl, 250 mM sucrose, 50 μg/ml digitonin, and 1 mM DTT) with a protease inhibitor mixture, and centrifuged for 5 min at 10,000 × g at 4 °C. The supernatant (cytoplasmic
fraction) and the pellet containing mitochondrial fraction were used for Western blot analysis.

**Statistical Analysis**—Data from populations of mitochondria from EM micrographs are represented as mean ± S.E. unless otherwise mentioned. Comparisons between the two groups were made using a Student’s *t* test unless otherwise stated. Statistical analyses were performed using Microsoft Excel and GraphPad Prism.

**RESULTS**

*ChChd3 Is Myristoylated at the N Terminus*—ChChd3 has a well conserved myristoylation site at the N-terminal Gly-2 and a PKA phosphorylation site at Thr-11 (Fig. 1A). N-Myristoylation is a co-translational modification known to promote membrane binding that is essential for proper protein localization or biological function (31). To determine whether ChChd3 is myristoylated, we immunoprecipitated transiently expressed FLAG-tagged ChChd3 from HEK293 cells and separated it by SDS-PAGE, and tryptic peptides were analyzed by mass spectrometry. Mass spectrometric analysis identified a peptide of *m/z* 859.5251, corresponding to the myristoylated N terminus (myrGGTASTR). Fragmentation of this peptide unequivocally showed that the N-terminal glycine is myristoylated (supplemental Fig. S1).

*ChChd3 Resides on the Inner Mitochondrial Membrane Facing the Intermembrane Space*—We initially identified ChChd3 in purified mouse liver mitochondrial fractions and later showed that both endogenous and transiently expressed ChChd3 is localized to mitochondria (15). To further define the submitochondrial location of ChChd3, we fractionated purified mouse liver mitochondria into OM, IMS, IM, and matrix compartments as described previously (24). Equal amounts of protein from each of these fractions were separated by SDS-PAGE and analyzed by immunoblotting by using antibodies against ChChd3 and known mitochondrial marker proteins. ChChd3 is enriched in the IM fraction similar to that of the IM marker protein, NDUFS3. M, matrix (C). SDS-PAGE and immunoblot analysis of trypsin-treated samples of mitochondria, swollen mitochondria, and submitochondrial particles (D).
pared with that of submitochondrial particles and pure mitochondria (Fig. 1D) suggesting that ChChd3 is located on the IM facing the IMS. When submitochondrial particles and mitochondrial membranes were solubilized with 1% Triton X-100, ChChd3 was digested completely. Proteolysis of ChChd3 was similar to that of OPA1 (Fig. 1D; 4), thus suggesting that ChChd3 is localized on the IM facing IMS.

Loss of ChChd3 in HeLa Cells Results in Abnormal Mitochondrial Morphology and Altered Levels of Drp1 and Opa1—To explore the functional role of ChChd3 in mitochondria, we silenced ChChd3 gene expression using RNAi. For this purpose, we generated a panel of HeLa clonal cell lines that stably express shRNA specific for ChChd3 or a scrambled control sequence. The mitochondrial morphology in the scrambled control (control-shRNA) and from two independent clones of ChChd3 knockdown cells was analyzed under confocal microscope for mitochondrial fragmentation and clumping. Mean ± S.D. from three independent experiments is shown. C, HeLa control, control-shRNA, and ChChd3-shRNA cell lysates were assessed for the changes in the protein levels of the key regulators of mitochondrial fusion and fission. ChChd3-shRNA1 and shRNA2 represent two different clones derived from a single shRNA sequence.

FIGURE 2. Loss of ChChd3 in HeLa cells results in abnormal mitochondrial morphology. A, mitochondria in ChChd3 knockdown cells are clumpy, fragmented, and clustered around the nucleus. Representative confocal microscopic images of HeLa-control, control-shRNA, and ChChd3-shRNA HeLa cells expressing matrix-targeted RFP (mito-RFP). Two independent clones of ChChd3-shRNA (ChChd3-shRNA clone 1 and ChChd3-shRNA clone 2) were analyzed to avoid the selection artifacts. Scale bar, 10 μm. B, quantification of mitochondrial abnormalities in ChChd3 knockdown cells. 300 cells each from the control and ChChd3 knockdown cells were analyzed under confocal microscope for mitochondrial fragmentation and clumping. Mean ± S.D. from three independent experiments is shown. C, HeLa control, control-shRNA, and ChChd3-shRNA cell lysates were assessed for the changes in the protein levels of the key regulators of mitochondrial fusion and fission. ChChd3-shRNA1 and shRNA2 represent two different clones derived from a single shRNA sequence.

pared with that of submitochondrial particles and pure mitochondria (Fig. 1D) suggesting that ChChd3 is located on the IM facing the IMS. When submitochondrial particles and mitochondrial membranes were solubilized with 1% Triton X-100, ChChd3 was digested completely. Proteolysis of ChChd3 was similar to that of OPA1 (Fig. 1D), an IM protein facing the IMS (4), thus suggesting that ChChd3 is localized on the IM facing IMS.

Loss of ChChd3 in HeLa Cells Results in Abnormal Mitochondrial Morphology and Altered Levels of Drp1 and Opa1—To explore the functional role of ChChd3 in mitochondria, we silenced ChChd3 gene expression using RNAi. For this purpose, we generated a panel of HeLa clonal cell lines that stably express shRNA specific for ChChd3 or a scrambled control sequence. The mitochondrial morphology in the scrambled control (control-shRNA) and from two independent clones of ChChd3 knockdown cells was assessed by using transiently expressed matrix-targeted RFP (mito-RFP). Interestingly, ~70% of the cells lacking ChChd3 showed fragmentation of the mitochondrial network and clustering of the mitochondria around the nucleus (Fig. 2, A and B) compared with the control-shRNA and control-HeLa cells, which displayed elongated and evenly distributed mitochondria (Fig. 2A).

Because it appeared that loss of ChChd3 results in an imbalance between mitochondrial fusion and fission, we next examined these cells for changes in protein levels of the key players of mitochondrial fusion (Mfn1, Mfn2, and OPA1) and fission (Drp1) processes (1). We found a significant increase in DRP1 and a decrease in both the long and short isoforms of OPA1 protein levels in ChChd3 knockdown cells (Fig. 2C). No changes in levels of Mfn1 and Mfn2 were observed (data not shown).

The increased fragmentation observed in ChChd3 knockdown cells could indicate either increased fission or decreased fusion in the absence of ChChd3. To distinguish these possibilities, we used the dominant negative mutant of the fission component DRP1, DRP1K38A. GFP-tagged DRP1 or DRP1K38A were co-expressed with mito-RFP in control-
shRNA and ChChd3-shRNA cells, and mitochondrial morphology was analyzed by fluorescence microscopy. As reported previously (32), expression of DRP1K38A in control-shRNA cells resulted in elongated and interconnected mitochondria, visibly different from those of the cells expressing WT DRP1 or GFP alone (Fig. 3). On the other hand, expression of DRP1K38A in cells lacking ChChd3 displayed punctiform mitochondria similar to those of DRP1WT and GFP-expressing cells indicating that the organelles are unable to fuse in the absence of ChChd3 (Fig. 3).

Loss of ChChd3 Expression Leads to Significant Defects in Energy Production—To test whether the alterations observed in the mitochondrial dynamics have affected mitochondrial function, we measured rates of endogenous, state 4, and uncoupler-stimulated mitochondrial respiration and glycolytic activity of control-shRNA and two clones of ChChd3-shRNA HeLa cells using a Seahorse extracellular flux analyzer. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) as a function of glycolytic lactate production were measured simultaneously by using the Seahorse extracellular flux analyzer in real time. Rates shown are the averages of four wells measured for 3 min after every 5 min. Also shown are the OCR and ECAR values after addition of 1 μg/mL oligomycin, 200 nM carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), and 100 nM roteneone/myxothiazol (Rot/Myx). C, cellular ATP levels in control-shRNA and ChChd3-shRNA HeLa cells were measured by luminescence-based CellTiter-Glo® cell viability assay. ATP levels were normalized to the protein levels. ChChd3-shRNA1 and shRNA2 represent two different clones derived from a single shRNA sequence. Error bars represent standard deviation from triplicate samples. p < 0.01.
simultaneously measured in the presence of 10 mM glucose, 10 mM pyruvate, and 2 mM glutamine as oxidizable substrates. Strikingly, knockdown of ChChd3 produced a dramatic decrease in rates of both the oxygen consumption and lactate production indicating significantly diminished respiratory and glycolytic capacity (Fig. 4, A and B).

We next assessed the cellular ATP levels in control-shRNA and ChChd3-shRNA cells in a luciferase-based luminescence reaction. Despite the drastically reduced capacity to generate ATP, the total cellular ATP level was reduced only 13% in the absence of ChChd3 (Fig. 4C). These data suggest that ChChd3 knockdown cells have
lower energy consumption and defective cellular metabolism characterized by reduced cellular oxygen consumption and glycolysis rates.

Diminished ChChd3 Expression Alters Crista Architecture—To further understand the changes in mitochondrial morphology and defective bioenergetics due to the loss of ChChd3, we analyzed the ultrastructure of mitochondria in ChChd3 knockdown cells by transmission electron microscopy. The transmission electron microscopy analysis revealed that loss of ChChd3 induced remarkable changes in the mitochondrial IM (Fig. 5). The majority of the mitochondria in ChChd3 knockdown cells have reduced crista content along with the partial remodeling of cristae from lamellar to tubular profiles (Fig. 5, A, panels c and d, and D)). Furthermore, often the mitochondria in ChChd3 knockdown cells were found to be completely devoid of cristae (Fig. 5, A, panel e, and C). Quantification of the membrane surface area of mitochondria from the control and ChChd3 knockdown cells showed that knockdown cells have a 50% reduction in the crista surface area compared with that of control cells (Fig. 5B). No significant change in the number of cristae per unit volume of mitochondria between the control and ChChd3 knockdown cells was found suggesting that crista fragmentation did not occur (Fig. 5E).

In addition to the alterations in the IM, the ChChd3 knockdown cells also showed clustering of mitochondria around the nucleus and large areas of cytoplasm devoid of mitochondria close to the nucleus as in control cells (Fig. 5). ChChd3 knockdown cells were about twice as high in number of mitochondria, with no significant increase in number of mitochondria, with no significant change in mitochondrial volume per cell volume (Fig. 5, G–I) compared with that of the control cells, thus suggesting an increase in mitochondrial fragmentation.

Recent studies have suggested that crista remodeling is accompanied by changes in CJ architecture (10, 14, 33). The IM proteins mitofilin and OPA1, which regulate crist morphology, have been shown to localize at the CJs (4, 12, 34). Studies by independent groups have suggested that during apoptosis disassembly of OPA1 oligomers at the CJs causes changes in the CJ diameter (10, 14). Down-regulation of mitofilin in HeLa cells resulted in complete loss of CJs (12). Because we noticed major alterations in crista structures in the absence of ChChd3, we decided to further analyze the morphology of the IM by using tomographic three-dimensional reconstructions to look into CJ opening diameter and density (Fig. 6). No changes in the number of CJs were observed in ChChd3 knockdown cells compared with that of the control-shRNA expressing cells (Fig. 6D). However, the CJ opening diameter in mitochondria in cells lacking ChChd3 is remarkably reduced to half the size (~8 nm) compared with that of control mitochondria (~16 nm, Fig. 6G), indicating that ChChd3 is involved in maintaining CJ architecture but not in their formation.

ChChd3 Interacts with Mitofilin, Sam50, OPA1, and HSP70—To further understand the role of ChChd3 in regulating mitochondrial structure, dynamics, and function, we sought to identify its potential binding partners. For this purpose, we immunoprecipitated the FLAG-tagged ChChd3 or vector control from HEK293 cells and analyzed the samples by MS/MS sequencing. MS/MS data identified two proteins, mitofilin and HSP70, exclusively in the ChChd3 FLAG sample (supplemental Fig. S2 and supplemental Table S1). These interactions were further confirmed by immunoblot with antibodies against mitofilin and HSP70 (Fig. 7A).

Following our findings, Xie et al. (35) reported ChChd3 as part of the 340-kDa complex immunoprecipitated with the mitofilin antibody. Sam50, metaxin 1, and metaxin 2, the components of the SAM complex on the OM involved in β-barrel protein assembly, have also been immunoprecipitated (36) in the same complex. Because the reported study was restricted to immunoprecipitation with mitofilin antibody alone, we further sought to systematically analyze the specificity of these protein-protein interactions in which ChChd3 is involved. Because of the lack of availability of antibodies for metaxin 1 and 2, we restricted our studies to Sam50 and ChChd3.
and mitofilin in this complex. Immunoprecipitation of FLAG-tagged ChChd3 from HEK293 cells showed the presence of Sam50 (Fig. 7A). In a reciprocal experiment, endogenous ChChd3 was co-purified from the immunoisolated samples of mitofilin FLAG and Sam50 FLAG (Fig. 7, B and C) further confirming these protein-protein interactions.

To characterize the binding regions of mitofilin and Sam50 on ChChd3, we mapped the regions of ChChd3 that are required for their interaction. For this, we used transiently expressed C-terminally FLAG-tagged mutants that lack the N-terminal 14 amino acids (ΔNT) or the chch domain (ΔCT) in HEK293 cells. Immunoprecipitation of these mutant proteins from HEK293 cells showed that ΔNT associates with mitofilin similar to that of the WT protein (Fig. 7D). However, interaction between ΔCT and mitofilin is significantly reduced compared with that of WT or ΔNT. In contrast, Sam50 showed efficient binding to ΔCT (Fig. 7D). On the other hand, ΔNT failed to bind Sam50 indicating that ChChd3 binds to mitofilin through the chch domain and to Sam50 through its N terminus. As we identified that ChChd3 is myristoylated at the N terminus, we hypothesized that N-myristoylation may be involved in binding to Sam50. To test this, we generated the G2A mutant of ChChd3 and assessed the ability of this mutant protein to pull down Sam50 and mitofilin. Although G2A can efficiently pull down mitofilin, it was unable to bind Sam50 (Fig. 7D), thus suggesting that ChChd3 binds to Sam50 via its myristoyl moiety or in a myristoylated conformation. It seems that in mitochondria, myristoylation recruits the N terminus of ChChd3 to the OM where the SAM complex is located, whereas the chch domain is recruited to the IM where it associates with mitofilin (Fig. 7I, model). HSP70 did not show any preference and was found to be associated with all the mutants (Fig. 7D). The chch domain proteins are synthesized in the cytosol and are imported into the mitochondria in a completely reduced form. Molecular chaperones HSP70 and HSP90 are known to bind the preproteins and prevent premature folding and to assist in transport to the mitochondria (37). Hence it is likely that HSP70 associates with ChChd3 in the reduced state in the cytoplasm before it is imported into the mitochondria (Fig. 7I, model).

Down-regulation of ChChd3 resulted in reduced OPA1 protein levels, impaired mitochondrial fusion, and cristae remodeling along with narrowing of the CJ diameter. OPA1 has been shown to be involved in regulating cristae remodeling.

FIGURE 6. Electron tomography reveals that cristae junctions in ChChd3 knockdown mitochondria are smaller than those in control mitochondria. a, 2.4-nm-thick slice through the tomographic volume of a control mitochondrion. Control mitochondria are generally longer than their ChChd3 knockdown counterpart. Two cristae junctions are shown (arrowheads) with the one at bottom having a very large opening. Scale bar, 200 nm and applies to all panels. b, 2.4-nm thick slice through the tomographic volume of five ChChd3 knockdown mitochondria. These mitochondria are generally smaller and often found close to each other suggesting fission has occurred. The amount of cristae present can differ remarkably (compare L, similar cristae complement to control mitochondria, with M, tiny mitochondrion devoid of cristae), and the matrix density can also differ substantially (compare M with R). Their cristae junction openings are characteristically smaller (arrowheads). c and d, side views of a segmented and surface-rendered inner membrane from a control mitochondrial volume with numbered cristae junctions. Six cristae junctions are shown on one side and nine on the other side. e and f, side views of a segmented and surface-rendered inner membrane from a ChChd3 knockdown mitochondrial volume showing smaller cristae junctions (numbered) than the control. Six cristae junctions are shown on one side and four on the other side. g, cristae junction openings in ChChd3 knockdown mitochondria are about half the size of control openings. The mean cristae junction width at its largest opening in tomographic reconstructions is compared. The number of measurements is shown above each bar. Error bar, S.E. (**, p < 0.01). h, density of cristae junctions is no different in control and ChChd3 knockdown mitochondria. The total number of cristae junctions per mitochondrial volume was counted and divided by the mitochondrial surface area derived from the tomographic volume to determine the cristae junction density. Error bar, S.E.
independently of its role in mitochondrial fusion (10, 14). Oligomers of OPA1 at the CJs are known to control the CJ opening diameter. Because the loss of ChChd3 leads to the alterations in crista morphology along with narrowing of CJ opening diameter, we hypothesized a plausible functional connection between ChChd3 and OPA1. Additionally, mitofilin, ChChd3, and OPA1 are localized in the same compartment in mitochondria, with IM facing the IMS. Hence we assessed the possibility of the complex between these three proteins. Immunoprecipitation experiments confirmed that both the ChChd3 and mitofilin could efficiently interact with OPA1 (Fig. 7, E and F). Interestingly, the soluble IMS form of OPA1 preferentially associated with both ChChd3 and mitofilin (Fig. 7, E and F). Furthermore, ChChd3 mutants ΔNT, ΔH9004/NT, and ΔH9004/NT interact with mitofilin and the soluble IMS isoform of OPA1. 5% of the total input is shown throughout.

FIGURE 7. ChChd3 interacts with Mitofilin, Sam50, HSP70, and OPA1. A–C, FLAG-tagged ChChd3 (A), mitofilin (B), and Sam50 (C) were transiently expressed in HEK293 cells and immunoprecipitated (IP) with FLAG resin. Eluted samples were analyzed on SDS-PAGE followed by immunoblot (IB) with the indicated antibodies. D, ChChd3 binds to mitofilin through the chch domain and to Sam50 through N-terminal myristoylation or myristoylated confirmation. E–H, ChChd3 and mitofilin preferentially interact with the shorter isoform of OPA1 in HEK293 cells (E–G) and in mitochondria (H). FLAG-tagged full-length WT ChChd3 (E) or FLAG-tagged mitofilin (F) or ChChd3 mutant proteins (G) were expressed in HEK293 cells and immunoprecipitated with FLAG resin. Sam50 levels are not shown in the input as the antibodies available for Sam50 failed to detect endogenous protein in total cell lysates of HEK293 cells. H, ChChd3 protein, immunoprecipitated from mouse liver mitochondria by using ChChd3 antibody, binds efficiently with mitofilin and the soluble IMS isoform of OPA1. 5% of the total input is shown throughout. I, proposed model for localization of ChChd3 in mitochondria. ChChd3 is synthesized in the cytoplasm and kept in a reduced and soluble form with the help of HSP70, before it is imported and folded in the mitochondria. In mitochondria, ChChd3 may exist at two discrete foci: 1) at CJ and (2) at contact sites (CS). At the CJs, ChChd3 would form a complex with mitofilin and OPA1, and at the contact sites it would associate with mitofilin and Sam50 thereby influencing the regulation of crista biogenesis and mitochondrial protein import, respectively. MF, mitofilin; IBM, inner boundary membrane.
G2A, and ΔCT showed reduced affinity toward binding to OPA1 (Fig. 7G). Analysis of these mutant proteins by immunofluorescence revealed that although WT protein is exclusively localized to mitochondria, ΔCT failed to localize to mitochondria. On the other hand, ΔNT and G2A are diffused throughout the cell and exhibit partial mitochondrial localization.

Hence, it is likely that the interaction between OPA1 and ChChd3 is specific to mitochondrial IMS where soluble OPA1 is generated by the cleavage of the full-length transmembrane OPA1. To further confirm this complex in mitochondria, we immunoprecipitated ChChd3 from purified mouse liver mitochondria and analyzed for OPA1 and mitofilin binding. ChChd3 showed efficient binding to mitofilin and to the soluble IMS form of OPA1 in mitochondrial samples (Fig. 7H). The interaction of ChChd3 with OPA1 together with a decrease in the protein levels of OPA1 and reduced mitochondrial fusion in ChChd3 knockdown cells (Figs. 2D and 3) suggest that ChChd3 may play an essential role in regulating OPA1 function, specifically the soluble IMS form.

ChChd3 Knockdown Cells Show a Drastic Reduction in the Protein Levels of Mitofilin and Sam50—Because we found that ChChd3 interacts with mitofilin, Sam50, and OPA1 (Fig. 7), and ChChd3 knockdown cells show reduced OPA1 levels (Fig. 2C), we analyzed the protein levels of mitofilin and Sam50. Immunoblot analysis of the total cell lysates of control-shRNA and ChChd3-shRNA cells revealed a drastic reduction in both the mitofilin and Sam50 proteins in ChChd3 knockdown cells (Fig. 8A). RT-PCR revealed no changes in mRNA levels (supplemental Fig. S3), suggesting that there is no effect in the transcription of these proteins, and the decrease in protein levels is due to differences in translation or post-translational mechanisms. The levels of HSP70, another ChChd3-associated protein, did not change in the ChChd3 knockdown cells (Fig. 8A).

Depletion of Sam50 has been shown to cause defects in the assembly of VDAC and TOM40 (36, 38). To determine whether the loss of Sam50 in ChChd3 knockdown cells resulted in defects in the assembly and stability of these proteins, we initially assessed the total cell lysates of control-shRNA- and ChChd3-shRNA-expressing cells for changes in these protein levels. No changes in TOM40 protein levels were observed. However, VDAC protein levels were reduced in ChChd3-shRNA cells (data not shown). To look for specific changes in mitochondrial protein levels, we separated soluble (cytoplasmic) and insoluble fractions (containing mitochondria) from the control-shRNA and ChChd3-shRNA cells and analyzed for VDAC and Tom40 levels (Fig. 8B). ChChd3 knockdown cells showed an ~40% reduction in VDAC levels in the membrane fraction, whereas Tom40 levels were not affected.

In addition to the reduction in VDAC levels, we found that IM proteins, AIF, and prohibitin levels are also reduced in the mitochondrial fraction of ChChd3 knockdown cells (Fig. 8B). When the oxidative phosphorylation complexes on the IM were analyzed in these samples, cytochrome c oxidase sub-

---

4 M. Darshi and S. S. Taylor, manuscript in preparation.
units, COX-II and COX-IV, showed a clear reduction in the mitochondrial fraction of ChChd3 cells (Fig. 8B).

Loss of ChChd3 Leads to Reduced Cell Proliferation and Increased Autophagy—Defects in mitochondrial structure, reduced cristae content, and reduced cellular bioenergetics in ChChd3 knockdown cells are further reflected in a reduced growth rate. When an equal number of control and ChChd3 knockdown cells were plated and counted manually, a 60% reduction in cell number was observed after 4 days (Fig. 9A).

To determine the cause for reduced cell number, we analyzed the control and ChChd3 knockdown cells for changes in apoptosis. No significant difference was observed when the cells were stained with annexin V to visualize apoptotic cells (data not shown). Also, no detectable changes in cleavage of poly(ADP-ribose) polymerase (PARP) were found in both the untreated as well as staurosporine-treated conditions (Fig. 9B). As there was no indication of increased apoptosis, the reduction in ChChd3 knockdown cell number is most likely attributable to decreased cellular proliferation. Consistent with this, immunoblotting of cell lysates for phosphorylated and total p70 S6 kinase revealed a decrease in both the protein levels in the ChChd3 knockdown cells (Fig. 9C), suggesting that these cells spend a longer time in the G1 phase and may be accelerating the processes leading to cellular senescence.

Because EM images of ChChd3 knockdown cells showed an increase in number of the vesicles, multivesicular bodies, lysosomes, and autophagosomes (Fig. 5A, panels f and g), we investigated a possible increase in autophagy in these cells by probing for the endogenous LC3 protein, a well known marker for autophagy (39). Upon initiation of autophagy, LC3 is cleaved to form LC3-II, and ChChd3 knockdown cells showed a clear increase in the LC3-II band compared with the control cells (Fig. 9D). Although growing evidence points toward the role of autophagy in maintaining homeostasis by degrading the dysfunctional organelles and proteins, autophagy has also been specifically shown to associate with the type II (nonapoptotic) programmed cell death (40). Because ChChd3 knockdown cells display severe defects in mitochon-
ChChd3 Regulates Crista Architecture

drial IM structure, it is likely that these abnormal mitochondria are being targeted for destruction by autophagy, and the elevated autophagy is also a possible reason for the decreased cell number observed in ChChd3 knockdown cells.

**DISCUSSION**

ChChd3 belongs to the subset of chch domain family proteins that are known to be primarily in the IMS of mitochondria and are characterized for their roles in protein import and as metallochaperones (22, 41). Although ChChd3 was identified in our laboratory a few years ago as a substrate for protein kinase A (15), the function of this protein is so far completely unknown. In this study, we describe the characterization of ChChd3 as a novel protein essential for maintaining cristal integrity and mitochondrial function. We provide evidence suggesting that ChChd3 is one of the key proteins that stabilizes protein complexes involved in maintaining cristal architecture and protein import, the two primary processes that regulate mitochondrial structure and function.

Down-regulation of ChChd3 in HeLa cells resulted in fragmentation and clustering of the mitochondrial network (Fig. 2A). Studies with the dominant negative mutant of Drp1, DRP1K38A, which is resistant to fission, showed that the mitochondria in ChChd3 knockdown cells have impaired fusion activity. Additionally, ChChd3 interacts preferentially with the soluble IMS form of OPA1. Recent studies have suggested the essential role of OPA1 not only in mitochondrial fusion but also in remodeling of cristae (33). Even though both the long and short isoforms have been shown to be essential in regulating mitochondrial fusion (42) and cristal morphology (10, 14), the individual role of these isoforms is not clearly understood. A recent immuno-EM study identified a differential distribution of the two yeast isoforms of OPA1 (Mgm1) across the IM (43). Long Mgm1 was found strongly enriched in the cristal membrane, and the short Mgm1 was preferentially localized on the OM/inner boundary membrane. Furthermore, by using various mutations in the GTPase domain, these authors showed that the functional GTPase domain is only required in short Mgm1 but not in long Mgm1 suggesting the idea of distinct function of each of these isoforms in mitochondria. It is likely that the fusion activity of OPA1 along with mitofusins on the OM is controlled by the s-OPA1 on the inner boundary membrane, whereas the cristal morphology is regulated by long OPA1 on the cristal membrane. Interaction of ChChd3 preferentially with soluble OPA1 and impaired fusion in ChChd3 knockdown cells indicate toward the potential involvement of ChChd3 in regulating the function of this isoform.

Depletion of ChChd3 resulted in major remodeling of the cristae and the CJ architecture (Figs. 5 and 6). Previous studies have suggested that mitofilin and OPA1 are located at the CJs and involved in regulating cristal morphology (12, 34). We demonstrate that ChChd3 interacts with mitofilin and OPA1, and loss of ChChd3 results in near loss of mitofilin and 50% reduction in OPA1 protein levels (Fig. 2C). This suggests the possibility that all three proteins are in a complex at the CJs, where ChChd3 is a scaffolding protein that stabilizes the protein complexes and thus is involved in maintaining the integrity of CJs and in the formation/stabilization of cristae.

We also found that ChChd3 and mitofilin interact with Sam50 (Fig. 7), the component of the SAM complex on the OM, involved in β-barrel protein assembly. Very few proteins have so far been known to regulate both the protein import and organelle morphology (44). The yeast protein, Mdm10, originally characterized for its role in mitochondrial dynamics and morphology has been shown to interact with SAM complex and is required for the β-barrel protein assembly (45). To date, no mammalian proteins have been identified with dual functions in biogenesis of mitochondrial proteins and organelle morphology. Our results suggest the possible involvement of ChChd3 in protein import and/or assembly via SAM complex in addition to its role in regulating cristal architecture.

The N-terminal POTRA domain of Sam50 is located in the IMS and has been shown to bind β-barrel precursor proteins in vitro (46). In the IMS, ChChd3 may have a role in transporting the precursor proteins to the SAM complex. A similar function was suggested for IMS-translocase of inner membrane proteins (47). However, so far there is no evidence showing the association of translocase of inner membrane proteins with the SAM complex.

As ChChd3 is localized to both the OM and IM fractions in the fractionated mitochondria and associates with both OM and IM proteins, we predict that ChChd3, together with mitofilin and Sam50, is located at contact sites where both the inner and outer membranes come together. These membrane contacts are known to be essential for various mitochondrial functions, including metabolite channeling, coordinated fusion, fission, protein transport, and also for maintaining structural integrity of outer and inner membranes (48, 49). Because CJs and contact sites are suggested to be two distinct structures on the IM and are not in preferential proximity to each other (49, 50), we propose that ChChd3 may be localized in discrete complexes at CJs and contact sites (Fig. 7I, model). At the CJs, ChChd3 is likely to be associated with mitofilin and OPA1, and at the contact sites it is expected to be in a complex with mitofilin and Sam50. It is likely that ChChd3 is dynamically distributed between these two distinct complexes under different conditions in the mitochondria.

The distinct morphological changes observed due to the knockdown of ChChd3 are more severe than the knockdown phenotypes of mitofilin, OPA1, or MICS1, the mitochondrial proteins previously known to be involved in regulating cristal morphology (11–13). Loss of mitofilin resulted in an increase in the surface area of IM, with the cristae having degraded to the form of concentric sheets (12). Down-regulation of OPA1 caused fragmentation of mitochondria and remodeling of cristae to reticular, curved, or ring-shaped structures (11). The cristae in MICS1-depleted mitochondria were observed to be curved and ring-like invaginations of the IM (13). In contrast, mitochondria in ChChd3 knockdown cells often did not contain any cristae. Those with cristae transitioned partly from lamellar to tubular cristae and overall showed a 50% reduction in the cristal membrane surface area, indicating that
either cristae were not formed properly or were disassembled more rapidly. Furthermore, loss of ChChd3 leads to a remarkable change in the CJ opening diameter without any significant changes in CJ number. This suggests that ChChd3 is not necessary for the formation of CJs; however, it is important for maintaining CJ architecture. On the contrary, loss of mitofilin was shown to affect the formation of CJs. Recent studies have established that CJ opening size depends on the OPA1 oligomers (10, 14), which are important to our finding that ChChd3 associates with OPA1 and are thus likely to have a role in OPA1 oligomerization and in maintaining CJ architecture. Consistent with the reduction in crista surface area, cells lacking ChChd3 also showed reduction in several IM protein levels. At this point, it is not clear if reduced crista content has triggered the reduction in IM proteins or the decreased crista content is the result of reduced levels of the proteins necessary for the proper formation and stabilization of the cristae.

The severe defect in mitochondrial morphology of ChChd3 knockdown cells is also reflected in strikingly lower rates of cellular respiration indicating a clear defect in mitochondrial function. Furthermore, the decrease in mitochondrial respiration is not compensated by an increase in glycolysis. It is likely that the deficiency of ChChd3 resulted in an overall reduced rate of substrate oxidation, energy production, and energy utilization that is consistent with the observed decreased rate of cell proliferation.

Our studies clearly suggest that ChChd3 is indispensable for maintaining crista structure and cellular metabolism. In a recent review, Perkins et al. (51) compiled findings showing that the central nervous system has significantly greater crista to mitochondrial surface area compared with the peripheral nervous system. Accordingly, ChChd3 (referred to as FLJ20420), which we showed to be essential for crista integrity, is highly abundant at synaptic membranes and in the neurons of rat brain throughout the gray matter, spinal cord, and at the dorsal root ganglion (16). Furthermore, recent studies have shown altered levels of ChChd3 in disease models of familial amyotrophic lateral sclerosis and ischemia (17, 52). Increasing lines of evidence have now indicated that the impairment of mitochondrial structure and function is one of the primary mechanisms behind motor neuron death in familial amyotrophic lateral sclerosis and cell death and injury in ischemia. Hence, it will be interesting to further understand whether ChChd3 plays a role in disease pathogenesis.

Our characterization of ChChd3 as a scaffolding protein for the SAM complex on the OM and mitofilin and OPA1 complex on the IM suggests that ChChd3 could be one of the key proteins that coordinate protein import and mitochondrial morphology, the two essential processes involved in proper functioning of mitochondria. Further studies are warranted to understand the dynamic localization of ChChd3 in these protein complexes and how ChChd3 regulates each of these protein complexes mechanistically. This will provide a better insight into the possible link between the essential processes that regulate organelle structure and function.

Acknowledgments—We appreciate the gift of DRP1 GFP cDNA from Dr. Stefan Strack, University of Iowa, and mito-RFP cDNA from Dr. Luca Scorrano, Venetian Institute of Molecular Medicine. We thank Susanna Petroysan for assistance with the mitochondrial preparations and Seahorse extracellular flux measurements; Michelle Yoon for assistance with the statistical measurements of mitochondrial morphology; Ohkyung Kwon for assistance with the confocal microscopy experiments; and Juniper Pennypacker for assistance with the site-directed mutagenesis. We also thank Drs. K. S. Madhusoodanan, Mira Sastri, and Christopher Eggers for critical reading of this manuscript.

REFERENCES
1. Chan, D. C. (2006) Annu. Rev. Cell Dev. Biol. 22, 79–99
2. Hoppins, S., Lackner, L., and Nunnari, J. (2007) Annu. Rev. Biochem. 76, 751–780
3. Chen, H., Detmer, S. A., EWald, A. J., Griffin, E. E., Fraser, S. E., and Chan, D. C. (2003) J. Cell Biol. 160, 189–200
4. Olichon, A., Emorine, L. J., Descoings, E., Pelloquin, L., Brichese, L., Gas, N., Guillou, E., Delettre, C., Valette, A., Hamel, C. P., Ducommun, B., Lenaers, G., and Belenguer, P. (2002) FEBS Lett. 523, 171–176
5. Smirnova, E., Griparic, L., Shurland, D. L., and van der Bliek, A. M. (2001) Mol. Biol. Cell 12, 2245–2256
6. Yoon, Y., Krueger, E. W., Oswald, B. J., and McNiven, M. A. (2003) Mol. Cell. Biol. 23, 5409–5420
7. Knott, A. B., and Bossy-Wetzel, E. (2008) Ann. N.Y. Acad. Sci. 1147, 283–292
8. Chen, H., and Chan, D. C. (2009) Hum. Mol. Genet. 18, R169–R176
9. Paumard, P., Vaillier, J., Coualy, B., Schaeffer, J., Soubannier, V., Mueller, D. M., Brethes, D., di Rago, J. P., and Velouras, J. (2002) EMBO J. 21, 221–230
10. Frezza, C., Cipolat, S., Martins de Brito, O., Micaroni, M., Beznoussenko, G. Y., Rudka, T., Bartoli, D., Polshuck, R. S., Danial, N. N., De Strooper, B., and Scorrano, L. (2006) Cell 126, 177–189
11. Olichon, A., Baricault, L., Gas, N., Guillou, E., Valette, A., Belenguer, P., and Lenaers, G. (2003) J. Biol. Chem. 278, 7743–7746
12. John, G. B., Shang, Y., Li, L., Renken, C., Mannella, C. A., Selker, J. M., Rangel, L., Bennett, M. J., and Zha, J. (2005) Mol. Cell. Biol. 16, 1543–1554
13. Oka, T., Sayano, T., Tamai, S., Yokota, S., Kato, H., Fuji, G., and Mihara, K. (2008) Mol. Biol. Cell 19, 2597–2608
14. Yamaguchi, R., Hartig, L., Perkins, G., Scott, R. T., D’Aidan, X., Kushnareva, Y., Kuswana, T., Ellisman, M. H., and Newman, S. C. (2008) Cell 31, 557–569
15. Schaulbe, S., King, C. C., Darahi, M., Koller, A., Shah, K., and Taylor, S. S. (2007) J. Biol. Chem. 282, 14952–14959
16. Dreger, M., Mika, J., Bieller, A., Janik, R., Gillen, C., Schaefer, M. K., Weihe, E., and Huch, F. (2005) J. Proteome Res. 4, 238–249
17. Fukuda, K., Zhang, F., Vien, A., Cashman, N. R., and Zhu, H. (2004) Mol. Cell. Proteomics 3, 1211–1223
18. Banci, L., Bertini, I., Ciofi-Baffoni, S., Janicka, A., Martinelli, M., Koziolowski, H., and Palumaa, P. (2008) J. Biol. Chem. 283, 7912–7920
19. Banci, L., Bertini, I., Cefaro, C., Ciofi-Baffoni, S., Gallo, A., Martinelli, M., Sideris, D. P., Katrakili, N., and Tokatlidis, K. (2009) Nat. Struct. Mol. Biol. 16, 198–206
20. Banci, L., Bertini, I., Ciofi-Baffoni, S., and Tokatlidis, K. (2009) FEBS Lett. 583, 1699–1702
21. Rigby, K., Zhang, L., Cobine, P. A., George, G. N., and Winge, D. R. (2007) J. Biol. Chem. 282, 10233–10242
22. Mesecke, N., Terziyska, N., Kozany, C., Baumann, F., Neupert, W., Hell, K., and Herrmann, J. M. (2005) Cell 121, 1059–1069
23. Mootha, V. K., Bunckenborg, J., Olsen, J. V., Hjerrild, M., Wisniewski, J. R., Stahl, E., Bolouri, M. S., Ray, H. N., Sihag, S., Kamal, M., Patterson, N., Lander, E. S., and Mann, M. (2003) Cell 115, 629–640
24. Pagliarini, D. J., Wiley, S. E., Kimple, M. E., Dixon, J. R., Kelly, P., Worby,
ChChd3 Regulates Crista Architecture

C. A., Casey, P. I., and Dixon, J. E. (2005) Mol. Cell 19, 197–207
25. Wu, M., Neilson, A., Swift, A. L., Moran, R., Tamagnine, J., Parslow, D., Armstead, S., Lemire, K., Orrell, J., Teich, J., Chomicz, S., and Ferrick, D. A. (2007) Anm. J. Physiol. Cell Physiol. 292, C125–C136
26. Gerencser, A. A., Mark, K. A., Hubbard, A. E., Divakaruni, A. S., Mehramian, Z., Nicholls, D. G., and Polster, B. M. (2009) J. Neurochem. 110, 990–1004
27. Kremer, J. R., Mastronarde, D. N., and McIntosh, J. R. (1996) J. Struct. Biol. 116, 71–76
28. Lawrence, A., Bouwer, J. C., Perkins, G., and Ellisman, M. H. (2006) J. Struct. Biol. 154, 144–167
29. Perkins, G. A., Renken, C. W., Song, J. Y., Frey, T. G., Young, S. J., Lamont, S., Martone, M. E., Lindsey, S., and Ellisman, M. H. (1997) J. Struct. Biol. 120, 219–227
30. Sun, M. G., Williams, J., Munoz-Pinedo, C., Perkins, G. A., Brown, J. M., Ellisman, M. H., Green, D. R., and Frey, T. G. (2007) Nat. Cell Biol. 9, 1057–1065
31. Resh, M. D. (1999) Biochim. Biophys. Acta 1451, 1–16
32. Smirnova, E., Shurland, D. L., Ryazantsev, S. N., and van der Bliek, A. M. (1998) J. Cell Biol. 143, 351–358
33. Yamaguchi, R., and Perkins, G. (2009) Biochim. Biophys. Acta 1787, 963–972
34. Odgren, P. R., Toukatly, G., Bangs, P. L., Gilmore, R., and Fey, E. G. (1996) J. Cell Sci. 109, 2253–2264
35. Xie, J., Marusich, M. F., Souda, P., Whitelegge, J., and Capaldi, R. A. (2007) FEBS Lett. 581, 3545–3549
36. Kozjak-Pavlovic, V., Ross, K., Benlasfer, N., Kimmig, S., Karlas, A., and Rudel, T. (2007) EMBO Rep. 8, 576–582
37. Young, J. C., Hoogenraad, N. J., and Hartl, F. U. (2003) Cell 112, 41–50
38. Humphries, A. D., Streitmann, I. C., Stojanovski, D., Johnston, A. J., Yano, M., Hoogenraad, N. J., and Ryan, M. T. (2005) J. Biol. Chem. 280, 11535–11543
39. Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., and Yoshimori, T. (2000) EMBO J. 19, 5720–5728
40. Klionsky, D. J., and Emr, S. D. (2000) Science 290, 1717–1721
41. Palumaa, P., Kangur, L., Voronova, A., and Sillard, R. (2004) Biochem. J. 382, 307–314
42. Song, Z., Chen, H., Fiket, M., Alexander, C., and Chan, D. C. (2007) J. Cell Biol. 178, 749–755
43. Zick, M., Duvezin-Caubet, S., Schäfer, A., Vogel, F., Neupert, W., and Reichert, A. S. (2009) FEBS Lett. 583, 2237–2243
44. Stojanovski, D., Rissler, M., Pfannschmidt, S., and Meisinger, C. (2006) Biochim. Biophys. Acta 1763, 414–421
45. Meisinger, C., Rissler, M., Chacinska, A., Szklarz, L. K., Milenkovic, D., Kozjak, V., Schönfisch, B., Lohaus, C., Meyer, H. E., Yaffe, M. P., Guiard, B., Wiedemann, N., and Pfanner, N. (2004) Dev. Cell 7, 61–71
46. Habib, S. I., Waizenegger, T., Niewienda, A., Paschen, S. A., Neupert, W., and Rapaport, D. (2007) J. Cell Biol. 176, 77–88
47. Wiedemann, N., Truscott, K. N., Pfannschmidt, S., Guiard, B., Meisinger, C., and Pfanner, N. (2004) J. Biol. Chem. 279, 18188–18194
48. Reichert, A. S., and Neupert, W. (2002) Biochim. Biophys. Acta 1592, 41–49
49. Perkins, G., Renken, C., Martone, M. E., Young, S. J., Ellisman, M., and Frey, T. (1997) J. Struct. Biol. 119, 260–272
50. Perkins, G. A., Renken, C. W., Frey, T. G., and Ellisman, M. H. (2001) J. Neurosci. Res. 66, 857–865
51. Perkins, G., Bossy-Wetzel, E., and Ellisman, M. H. (2009) Exp. Neurol. 218, 183–192
52. Kavazis, A. N., Alvarez, S., Talbert, E., Lee, Y., and Powers, S. K. (2009) Am. J. Physiol. Heart Circ. Physiol. 297, H144–H152